PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:PHN - IT0005274094 - Common Stock
59.2 EUR
-0.3 (-0.5%)
Taking everything into account, PHN scores 7 out of 10 in our fundamental rating. PHN was compared to 12 industry peers in the Personal Care Products industry. PHN gets an excellent profitability rating and is at the same time showing great financial health properties. PHN is valued quite expensively, but it does show have an excellent growth rating. With these ratings, PHN could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- PHN had positive earnings in the past year.
- PHN had a positive operating cash flow in the past year.
- In the past 5 years PHN has always been profitable.
- Each year in the past 5 years PHN had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 20.41%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- PHN has a better Return On Equity (38.54%) than 100.00% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 26.24%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- PHN had an Average Return On Invested Capital over the past 3 years of 17.21%. This is significantly above the industry average of 12.19%.
- The 3 year average ROIC (17.21%) for PHN is below the current ROIC(26.24%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.41% | ||
| ROE | 38.54% | ||
| ROIC | 26.24% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
1.3 Margins
- Looking at the Profit Margin, with a value of 13.48%, PHN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
- In the last couple of years the Profit Margin of PHN has declined.
- Looking at the Operating Margin, with a value of 21.87%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- PHN's Operating Margin has been stable in the last couple of years.
- With an excellent Gross Margin value of 97.04%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.87% | ||
| PM (TTM) | 13.48% | ||
| GM | 97.04% |
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PHN is creating value.
- Compared to 1 year ago, PHN has about the same amount of shares outstanding.
- The number of shares outstanding for PHN has been reduced compared to 5 years ago.
- PHN has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 10.09 indicates that PHN is not in any danger for bankruptcy at the moment.
- The Altman-Z score of PHN (10.09) is better than 100.00% of its industry peers.
- The Debt to FCF ratio of PHN is 2.70, which is a good value as it means it would take PHN, 2.70 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of PHN (2.70) is better than 66.67% of its industry peers.
- A Debt/Equity ratio of 0.28 indicates that PHN is not too dependend on debt financing.
- PHN's Debt to Equity ratio of 0.28 is fine compared to the rest of the industry. PHN outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 2.7 | ||
| Altman-Z | 10.09 |
ROIC/WACC3.3
WACC7.96%
2.3 Liquidity
- PHN has a Current Ratio of 2.06. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 2.06, PHN belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
- A Quick Ratio of 1.75 indicates that PHN should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 1.75, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.75 |
3. Growth
3.1 Past
- PHN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.20%, which is quite impressive.
- PHN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.63% yearly.
- The Revenue has grown by 15.06% in the past year. This is quite good.
- Measured over the past years, PHN shows a quite strong growth in Revenue. The Revenue has been growing by 16.59% on average per year.
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
3.2 Future
- Based on estimates for the next years, PHN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.13% on average per year.
- The Revenue is expected to grow by 13.74% on average over the next years. This is quite good.
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 24.16 indicates a rather expensive valuation of PHN.
- Based on the Price/Earnings ratio, PHN is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
- PHN's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.38.
- The Price/Forward Earnings ratio is 24.24, which indicates a rather expensive current valuation of PHN.
- PHN's Price/Forward Earnings ratio is in line with the industry average.
- PHN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.16 | ||
| Fwd PE | 24.24 |
4.2 Price Multiples
- PHN's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PHN is more expensive than 66.67% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 75.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 69.96 | ||
| EV/EBITDA | 13.53 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- PHN has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as PHN's earnings are expected to grow with 15.13% in the coming years.
PEG (NY)3.87
PEG (5Y)1.65
EPS Next 2Y13.31%
EPS Next 3Y15.13%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.66%, PHN has a reasonable but not impressive dividend return.
- Compared to an average industry Dividend Yield of 2.05, PHN has a dividend in line with its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.85, PHN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.66% |
5.2 History
- On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- 40.63% of the earnings are spent on dividend by PHN. This is a bit on the high side, but may be sustainable.
- The dividend of PHN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP40.63%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
BIT:PHN (1/19/2026, 12:29:18 PM)
59.2
-0.3 (-0.5%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-11 2026-05-11
Inst Owners17.49%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap573.06M
Revenue(TTM)175.08M
Net Income(TTM)23.61M
Analysts82.86
Price Target82.62 (39.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.66% |
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP40.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.16 | ||
| Fwd PE | 24.24 | ||
| P/S | 3.27 | ||
| P/FCF | 69.96 | ||
| P/OCF | 46.5 | ||
| P/B | 9.36 | ||
| P/tB | 15.35 | ||
| EV/EBITDA | 13.53 |
EPS(TTM)2.45
EY4.14%
EPS(NY)2.44
Fwd EY4.13%
FCF(TTM)0.85
FCFY1.43%
OCF(TTM)1.27
OCFY2.15%
SpS18.09
BVpS6.33
TBVpS3.86
PEG (NY)3.87
PEG (5Y)1.65
Graham Number18.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.41% | ||
| ROE | 38.54% | ||
| ROCE | 45.24% | ||
| ROIC | 26.24% | ||
| ROICexc | 32.19% | ||
| ROICexgc | 49.25% | ||
| OM | 21.87% | ||
| PM (TTM) | 13.48% | ||
| GM | 97.04% | ||
| FCFM | 4.68% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 2.7 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 97.13% | ||
| Cap/Sales | 2.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.97% | ||
| Profit Quality | 34.7% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.75 | ||
| Altman-Z | 10.09 |
F-Score7
WACC7.96%
ROIC/WACC3.3
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%
EBIT growth 1Y14.83%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.16%
EBIT Next 3Y18.62%
EBIT Next 5Y9.65%
FCF growth 1Y144.25%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y38.33%
OCF growth 3Y0.14%
OCF growth 5Y11.34%
PHARMANUTRA SPA / PHN.MI FAQ
What is the fundamental rating for PHN stock?
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.
Can you provide the valuation status for PHARMANUTRA SPA?
ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.
What is the profitability of PHN stock?
PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.
How financially healthy is PHARMANUTRA SPA?
The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.
Is the dividend of PHARMANUTRA SPA sustainable?
The dividend rating of PHARMANUTRA SPA (PHN.MI) is 5 / 10 and the dividend payout ratio is 40.63%.